The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / EULAR Releases 2016 Recommendations on RA Management

EULAR Releases 2016 Recommendations on RA Management

July 14, 2017 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
racorn/shutterstock.com

racorn/shutterstock.com

Management of rheumatoid arthritis (RA) is complex. The ever-expanding availability of new drugs requires that rheumatologists and patients constantly consider treatment strategies and targets aimed at both disease control and symptom relief while remaining cognizant of the increasing high cost of emerging medications. Given such complexity, guidelines to inform rheumatologists about the most recent developments on managing RA have been appearing every three years or so.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
Explore This Issue
July 2017
Also By This Author
  • High Cost of Specialty Drugs Demands Action

In 2015, the ACR published an updated guideline; previous versions were published in 2012 and 2008.1-3 Most recently, the European League Against Rheumatism (EULAR) released its RA guidelines updated in 2016; previous ones were published in 2013 and 2010.4-6 The frequency of these updated guidelines suggests the importance for rheumatologists to keep up with the fast pace of the evidence to ensure the many and new treatment options available are tailored to individual patients and offered to all patients. This is particularly important given the high cost of many of the agents, such as biologics, that limit their widespread use.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This is aptly stated in the 2016 EULAR guidelines: “Management recommendations on the approach to treating patients with RA have become increasingly useful in providing physicians, patients, payers, regulators and other healthcare suppliers with evidence-based guidance supported by the views of experts involved in many of these novel developments.”4

This article highlights key findings and recommendations from the most current EULAR RA guideline. Drawing on the most current evidence to date, the 2016 EULAR update continues to support treatment strategies and specific treatment recommendations found in previous EULAR and ACR guidelines. Both guidelines emphasize treat-to-target strategies aimed at disease control, along with symptom relief, and offer specific treatment recommendations to help patients achieve this goal. Importantly, they now highlight the need to achieve and maintain treatment control.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The following sections focus on specific, new evidence-based recommendations for first- and second-line treatments, as well as tapering patients off therapies once persistent remission is achieved.

Foundations for Treatment Decisions & Goals

One change to the 2016 EULAR guidelines is the higher emphasis placed on basing treatment decisions not only on disease activity, but importantly, on such patient factors as comorbidities. This change is reflected in the four overarching principles that the guidelines provide (see Table 1). As noted in Table 1, principle B—Treatment decisions are based on disease activity and other patient factors, such as progression of structural damage, comorbidities and safety issues—moved from being a recommendation in the 2010 guideline to foundational in the 2016 guideline, reflecting the importance of considering comorbidities in treatment decisions.

Pages: 1 2 3 4 5 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: drug therapy, EULAR, European League Against Rheumatism, Management, patient care, recommendations, Rheumatic Disease, Rheumatoid arthritis, TreatmentIssue: July 2017

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • Updated EULAR Recommendations for Early Arthritis; Plus FDA Approves New Abuse-Deterrent Morphine Sulfate

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)